Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

NCT04726553 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: Anifrolumab
DRUG: Standard of Care

Sponsor

Oklahoma Medical Research Foundation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]